Reference number(s)
2388-H

SPECIALTY QUANTITY LIMIT PROGRAM

REVLIMID (lenalidomide)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization. The recommended dosing parameters for the treatment or prevention of multiple myeloma, myelodysplastic syndrome or mantle cell lymphoma fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Revlimid (lenalidomide) capsules 2.5mg	28 per 28 days	Multiple myeloma: 25 mg once daily orally on days 1-21 of repeated 28-day cycles. Multiple myeloma maintenance therapy following autologous hematopoietic stem cell transplantation: 10 mg once daily on days 1-28 of repeated 28-day cycles. After 3 cycles of maintenance therapy, the dose can be increased to 15 mg once daily if tolerated. Myelodysplastic syndromes: 10 mg once daily Mantle cell lymphoma: 25 mg once daily orally on days 1-21 of repeated 28-day cycles
Revlimid (lenalidomide) capsules 5mg	28 per 28 days	
Revlimid (lenalidomide) capsules 10mg	28 per 28 days	
Revlimid (lenalidomide) capsules 15mg	28 per 28 days	
Revlimid (lenalidomide) capsules 20mg	21 per 28 days	
Revlimid (lenalidomide) capsules 25mg	21 per 28 days	

III. REFERENCES

1. Revlimid [package insert]. Summit, NJ: Celgene Corporation; December 2017.

CVS caremark™